Interestingly, we didn’t found documented information about the role of IDO inhibitor on CD133+ cancer stem cells (CSC), while our results showed that 1-MT with/without tumor lysate vaccine significantly reduced CD133+ cells viability in treated tumor tissues, which suggests that IDO motif role is orchestrated by CSC in the tumor microenvironment. The gene discussed is IDO1; the disease is neoplasm.